Share these talks and lectures with your colleaguesInvite colleagues
Prof. Mark Cragg University of Southampton, UK1 Talk
Mark Cragg obtained his PhD in 1998 and did his postdoctoral studies in Southampton with Martin Glennie and in Melbourne, Australia with Andreas Strasser before starting his own group in 2007. His research concerns how therapeutics result in tumour regression with a focus on antibodies and small molecules. The aim... read moreis to understand how these therapeutics delete tumour cells, how resistance occurs and how it might be overcome. Over the last decade, he has investigated many different therapeutic agents such as rituximab, bexxar, imatinib, gefitinib, cetuximab and tarceva and has been involved in the development of next generation antibody reagents such as ofatumumab and obinutuzumab, as well as first in class antibodies such as BI-1206.